HeartWare to Present at The Canaccord Genuity 30th Annual Growth Conference
FRAMINGHAM, Mass. and SYDNEY, Aug. 4 HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CFO David McIntyre is scheduled to make an investor presentation at the Canaccord Genuity 30th Annual Growth Conference on Wednesday, August 11, at 3:30 pm EDT. The conference will be held August 10-12 at the InterContinental Boston.
A live webcast of the Company's presentation at the conference will be available via a link provided at www.heartware.com. An archived replay of the presentation will also be available shortly after the presentation time for a period of 90 days.
About HeartWare International
HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. HeartWare has received CE Marking for the HeartWare System in the European Union. The device is currently the subject of United States clinical trials for two indications: destination therapy and bridge-to-transplant under a continued access protocol. For additional information, please visit the company's website at www.heartware.com.
HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.
For further information: Christopher Taylor HeartWare International, Inc. Email: email@example.com Phone: +1 508 739 0864
SOURCE HeartWare International, Inc.
You May Also Like